Jordan Berlin, MD, shares an overview of new treatment options and trials in pancreatic cancer at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Similar Outcomes With Maintenance Olaparib for gBRCA-Mutated Pancreatic Cancer, Regardless of Patient Age
The safety of maintenance olaparib for gBRCA-mutated metastatic pancreatic cancer is consistent regardless of patient age, according to data presented at the ESMO World Congress on GI Cancer.
Findings from a study presented at the ESMO World Congress on GI Cancer posit that a nomogram can conveniently predict survival in patients with unresectable pancreatic cancer.
Long-Term Study Shows Improved Survival With Adjuvant Gemcitabine Plus Capecitabine for Pancreatic Cancer
Long-term outcomes of the ESPAC-4 trial showed improved survival and slightly less toxicity with adjuvant gemcitabine plus capecitabine versus gemcitabine alone for resected pancreatic cancer.
Anetumab ravtansine yielded manageable safety and encouraging antitumor activity in a study of heavily pretreated patients with mesothelin-expressing solid tumors.
The FDA has approved pemigatinib for the treatment of adults with certain types of pretreated, advanced cholangiocarcinoma.
Molecularly-matched treatments significantly increased OS in patients with pancreatic cancer and actionable molecular alteration in a retrospective Know Your Tumor registry analysis.
A link exists between disease progression and reduced QoL in patients with metastatic breast, pancreatic, lung, and colorectal cancers.